# Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

> **NCT00981084** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Missouri, Kansas City** · enrollment: 33 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** armodafinil

## Key facts

- **NCT ID:** NCT00981084
- **Lead sponsor:** University of Missouri, Kansas City
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981084, "Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00981084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*